In yesterday’s Wall Street session, Xilio Therapeutics Inc (NASDAQ:XLO) shares traded at $1.29, down -12.84% from the previous session.
XLO stock price is now 33.35% away from the 50-day moving average and 34.78% away from the 200-day moving average. The market capitalization of the company currently stands at $59.03M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $7, Chardan Capital Markets recently initiated with Buy rating for Xilio Therapeutics Inc (NASDAQ: XLO). On January 10, 2022, H.C. Wainwright recently initiated its ‘Buy’ rating on the stock quoting a target price of $36, while ‘Raymond James’ rates the stock as ‘Outperform’
In other news, Frankenfield Christopher James, Chief Financial Officer sold 6,954 shares of the company’s stock on Jan 02 ’25. The stock was sold for $6,841 at an average price of $0.98. Upon completion of the transaction, the Chief Financial Officer now directly owns 12,421 shares in the company, valued at $16023.09. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 02 ’25, SVP, FINANCE AND ACCOUNTING Brennan Kevin M. sold 1,803 shares of the business’s stock. A total of $1,774 was realized by selling the stock at an average price of $0.98. This leaves the insider owning 3,197 shares of the company worth $4124.13. A total of 55.37% of the company’s stock is owned by insiders.
During the past 12 months, Xilio Therapeutics Inc has had a low of $0.50 and a high of $1.93. As of last week, the company has a debt-to-equity ratio of 0.40, a current ratio of 1.67, and a quick ratio of 1.67. The fifty day moving average price for XLO is $0.96342 and a two-hundred day moving average price translates $0.956155 for the stock.
The latest earnings results from Xilio Therapeutics Inc (NASDAQ: XLO) was released for 2024-09-30. The net profit margin was -1359.37% and return on equity was -170.96% for XLO. For the current quarter, analysts expect XLO to generate $3.3M in revenue.
